Objectives: The previous finding of an immunologic response primarily directed against transglutaminase (TG)6 in patients with gluten ataxia (GA) led us to investigate the role of TG6 antibodies in diagnosing GA.
has already been shown that patients with GA have an immunologic response primarily directed against TG6 even in the absence of enteropathy. 6 In this study, we demonstrated that TG6 antibodies are sensitive and specific in diagnosing GA and also that they are gluten-dependent.
METHODS Patient selection. This was a prospective cohort study. Patients were recruited from the ataxia, gluten/neurology, CD, and movement disorders clinics based at the Royal Hallamshire Hospital (Sheffield, UK). In addition, well-characterized sera from patients with CD before and after the introduction of a gluten-free diet were provided from the CD clinic of Tampere University Hospital (Tampere, Finland). All recruited patients with ataxia had clinical evidence of cerebellar ataxia, and cerebellar atrophy was confirmed on MRI (figure 1 illustrates the typical findings of cerebellar atrophy in a patient with GA). Details of the MRI findings in patients with GA have been previously reported. 7 We excluded patients with peripheral neuropathy (particularly sensory ganglionopathy) to avoid confusion with patients with sensory rather than cerebellar ataxia.
Patients were divided into 2 groups: idiopathic sporadic ataxia negative for antigliadin antibodies (AGA), TG2 antibodies, and endomysial antibodies (EMA) (n 5 80), or GA based on the original definition, i.e., idiopathic cerebellar ataxia with positive antigliadin IgA and/or IgG antibodies irrespective of positivity for TG2 and EMA (n 5 48). Patients from both groups had been investigated extensively for all other causes of ataxia, including common genetic causes, with no alternative cause identified. Patients with a history of long-term phenytoin treatment or chronic alcohol excess were excluded. Neurologic control groups included patients with genetically confirmed neurologic and neurodegenerative conditions (29 patients with genetic ataxias, 7 patients with Huntington disease, and 46 patients with idiopathic Parkinson disease; total 5 82). A group of patients with CD (n 5 50) presenting to the gastrointestinal clinic in Sheffield and a healthy control group (n 5 57) were also included in the study.
Standard protocol approvals, registrations, and patient consents. The South Yorkshire Research Ethics Committee approved the study, and all patients (UK-based) provided written informed consent. For the patients with CD recruited from Tampere, Finland, local ethics approval was obtained and all patients provided written informed consent. Serologic testing. All UK patients were tested for serologic evidence of GRD using EMA, AGA IgG and IgA, and TG2 antibodies. Serologic testing was performed using commercially available ELISAs for antigliadin IgG and IgA and for TG2 antibodies (Aesku diagnostics) and immunofluorescence for EMA (Inova diagnostics). The serum was collected before patients starting a gluten-free diet. Serum of the Finnish CD patient cohort was assessed for TG2 IgA using the ELISA based on the open conformation of human recombinant TG2 (Zedira, Darmstadt, Germany).
Determination of anti-TG6 IgA and IgG was done using inhouse ELISAs. The methodology has been described in detail elsewhere. 6 Full-length human TG6 produced in SF9 cells was obtained from Zedira and diluted to 2 mg/mL in 20 mM Tris/ HCl, 300 mM NaCl, pH 7.6, for coating of high-capacity, protein-binding, 96-well plates (Immulon 2HB). Results with this antigen were comparable to those obtained with recombinant TG6 produced in house in Escherichia coli. The Finnish sample cohort was assessed using the recently revised commercial TG6 ELISAs (E003/E004, Zedira) and results were confirmed in an in-house ELISA. Human leukocyte antigen (HLA) typing was performed by the regional blood-transfusion service.
Enteropathy and GRD-associated mucosal IgA deposits.
Patients with ataxia and positive AGA routinely underwent gastroscopy and duodenal biopsy to establish the presence of enteropathy. In addition, 15 consecutive patients with idiopathic sporadic ataxia and negative serology for AGA, EMA, and TG2 antibodies underwent duodenal biopsy. All biopsies were histologically assessed for evidence of enteropathy (triad of villous atrophy, crypt hyperplasia, and increase in intraepithelial lymphocytes) as well as for the presence of mucosal TG-specific IgA deposits using established methodology. 3, 4 Statistics. Spearman rank correlation and Wilcoxon rank sum test were performed using PRISM version 4.0 (GraphPad Software, Inc., La Jolla, CA) and a 95% confidence interval.
RESULTS Prevalence of TG6 antibodies in the study and control groups. Figure 2 shows a flow chart summarizing the results for patients with cerebellar ataxia. We recruited 80 patients (65 had serologic testing for TG6 and 15 had duodenal biopsies before being tested for TG6) with idiopathic sporadic ataxia and no serologic evidence of gluten sensitivity (negative IgA and IgG AGA, EMA, and TG2 antibodies) and 48 patients with GA as defined by the original definition, i.e., idiopathic sporadic ataxia with circulating IgA and/or IgG AGA. The healthy control group (with no serologic evidence of gluten sensitivity) comprised 57 subjects, the neurologic control group 82 patients, and the CD group (patients presenting to the gastroenterologists) 50 patients. The prevalence of TG6 antibodies (IgG, IgA, or both) in these groups was as follows: 21/65 patients (32%) with idiopathic sporadic ataxia (all negative for AGA, EMA, and TG2 antibodies), 35/48 patients (73%) with sporadic ataxia and positive AGA (the original definition of GA), 2/57 (4%) of healthy controls, 4/82 (5%) of the neurology controls, and 16/50 (32%) in CD groups (UK cohorts).
Enteropathy. Not all of the patients in each group agreed to a duodenal biopsy. Sixteen of 38 patients (42%) with sporadic ataxia and positive AGA (the original definition of GA) who underwent duodenal biopsy had evidence of enteropathy, i.e., had CD. The prevalence of enteropathy in patients positive for TG6 antibodies (irrespective of the presence of AGA) and ataxia was 18 of 35 (51%). One of 15 patients with idiopathic sporadic ataxia negative for AGA, EMA, and TG2 antibodies had enteropathy.
IgA deposits on duodenal biopsies. Fifteen consecutive patients of the 80 in the idiopathic sporadic ataxia group (who had no evidence of circulating IgA and IgG AGA, EMA, or TG2 antibodies) underwent duodenal biopsies before being tested for TG6 antibodies. Five of 15 patients had duodenal IgA deposits against TG2, and 1 of these 5 patients had evidence of enteropathy. Four (including the patient with enteropathy) of these 5 cases were positive for TG6 antibodies on subsequent testing. Testing for TG6 was done blind to the result of the duodenal biopsy. Figure 3 illustrates examples of positive and negative IgA deposits against TG2 on duodenal biopsies.
Correlation of type of antibody and HLA type. More than 95% of patients with GA and enteropathy had the DQ2 or DQ8 HLA type as is the case with patients with CD. Within the groups of patients with ataxia, the percentage of patients with circulating antibodies to TG2, TG6, and AGA that had the HLA DQ2/DQ8 was 82%, 78%, and 73%, respectively. The difference between the groups was not significant.
Gluten dependence of TG6 autoantibodies. We have previously shown that patients with GA respond to a gluten-free diet. 8 Gluten dependence of TG6 autoantibodies has recently been questioned in a study from Finland. 9 To further evaluate in an unbiased way whether production of TG6 antibodies is linked to gluten intake, a cohort of 86 consecutive Finnish patients presenting to the gastroenterologists who were then diagnosed with CD and responded to a gluten-free diet were tested for autoantibodies to TG6. The serologic analysis was conducted in a blinded manner. The prevalence of TG6 autoantibodies in this Finnish cohort was 14% (12/86). The cases positive for TG6 autoantibodies were patients with CD who had abdominal symptoms and mild malabsorption (table). None of these patients had known neurologic symptoms. There was no correlation between TG2 IgA titers and titers of TG6 antibodies, either when considering the entire cohort (TG6 IgA: r 5 0.0593, p 5 0.588; TG6 IgG: r 5 0.012, p 5 0.913) or only the anti-TG6-positive patients (TG6 IgA: r 5 0.247, p 5 0.430; TG6 IgG: r 5 0.080, p 5 0.800). In 11 of these 12 cases, antibody titers were substantially lower after 1 year on a gluten-free diet (table) . Even though the number of untreated patients with CD testing positive for TG6 antibodies was lower than expected (in comparison to the Sheffield cohort), the decrease in antibody titers was significant on a gluten-free diet (TG6 IgA: p 5 0.027; TG6 IgG: p 5 0.043).
DISCUSSION This study examined the potential role of autoantibodies against TG6 (a brain-expressed TG 10 ) in the diagnosis of GA. Seventy-three percent of patients with idiopathic sporadic ataxia positive for AGA, the original definition of GA, were also positive for TG6 antibodies. This observation suggests a correlation between AGA and TG6 positivity but does not clarify whether TG6 antibodies are more sensitive or specific for GA than AGA. The prevalence of TG6 Figure 2 Flow chart summarizing the results of TG6 testing of all groups A flow chart summarizing the different ataxia groups tested for TG6 antibodies, the presence of enteropathy and of IgA deposits against TG2. The prevalence of TG6 antibodies compares with 4% in healthy controls, 5% in neurology control groups and 32% in patients with celiac disease presenting to gastroenterologists. AGA 5 antigliadin antibodies; EMA 5 endomysial antibodies; Ig 5 immunoglobulin; TG 5 transglutaminase.
autoantibodies in the healthy and neurology control groups was much less (4% and 5%) than that reported for AGA (12%). 11 Of note is also the finding that 32% of patients with idiopathic sporadic ataxia with negative serology for all other GRD serologic markers were positive for TG6. This suggests that the prevalence of GA may be even higher than previously thought. 12 
Figure 3
Examples of negative and positive IgA deposits against TG2 on duodenal biopsies
An example of a negative (top row) and positive (bottom row) staining for IgA deposits against TG2 on duodenal biopsies from 2 patients with idiopathic sporadic ataxia. The presence of such deposits represents a reliable marker of the spectrum of gluten-related disorders. The conventional histologic examination of these biopsies was normal. Ig 5 immunoglobulin; TG 5 transglutaminase. The specificity of these antibodies in identifying enteropathy among patients with ataxia was 42% for those patients positive for AGA vs 51% for those patients positive for TG6 antibodies. Within the ataxia patient population, the proportion of patients with circulating TG2 and TG6 antibodies with the appropriate HLA (as seen in CD DQ2 or DQ8) is similar, 82% and 78%, respectively. Enteropathy, however, is not a prerequisite for the diagnosis of GA, and what we were interested in was a reliable serologic marker for GA with or without enteropathy.
IgA deposits against TG2 in gut biopsies have been shown to be a reliable marker of the whole spectrum of GRDs and can be found in patients with otherwise normal histologic examination of the gut mucosa. Such deposits are a reliable predictor of future development of enteropathy 3, 13 and have been found in patients with GA without enteropathy. 4 We therefore investigated the presence of such deposits in 15 consecutive patients with idiopathic sporadic ataxia, serologically negative for AGA, TG2 antibodies, and EMA. Five of 15 had IgA deposits against TG2 on small bowel biopsies, one of whom had enteropathy (villous atrophy, crypt hyperplasia, and increase in the intraepithelial lymphocytes) in keeping with CD. Serum from all 15 patients was subsequently tested for circulating TG6 antibodies-4 patients were positive, all of whom were patients with IgA deposits against TG (one had frank enteropathy). This suggests that circulating TG6 antibodies can be a more sensitive marker for GA when compared with AGA, EMA, and TG2 antibodies.
The mechanism by which the 1 patient presenting with ataxia had enteropathy despite negative serology for EMA, AGA, and TG2 antibodies is of interest. It may imply that the characteristic and normally overwhelming autoantibody response seen in CD is not always a requirement for development of small-bowel lesions. This finding could also indicate that an immunologic response primarily directed toward another TG isotype, TG6 in this case, can lead to enteropathy. Similar to TG2, the autoantigen in CD, TG6 is also capable of deamidating gluten peptides and generate major T-cell epitopes, an important immunologic step in leading to organ damage.
14 Because TG6 is primarily expressed in the CNS, this finding raises the interesting question of whether the gut or the cerebellum primed the immunologic response to TG6. The importance of TG6 in cerebellar functioning has recently been emphasized by linkage of mutations in the human TGM6 gene with familial spinocerebellar ataxia. 15 This lends further credence to TG6 being the real target of the autoimmune response in GA that causes cerebellar degeneration. Some further support for this notion comes from the observation that anti-TG antibodies cause ataxia in a mouse model, although this response was not isotypespecific. 16 We did not find any correlation between serum levels of antibodies and severity of ataxia. We think that this is either attributable to the fact that the severity of the ataxia is dependent on the duration of the disease while untreated, or, given that the immunologic response is primarily within the CNS, peripheral blood estimation of TG6 does not necessarily reflect the level of antibodies and the strength of the immunologic response within the CSF and the CNS. We have also demonstrated for the first time that TG6 antibodies are gluten-dependent based on the observation that the TG6 antibody titer significantly reduces within a year of adherence to a gluten-free diet.
In this study, 32% of patients (UK cohort) with newly diagnosed CD presenting to the gastroenterologist were positive for TG6 antibodies. In the Finnish cohort, the prevalence of TG6 antibodies was 14%. It is not yet clear whether patients with CD and positive TG6 antibodies are the ones susceptible to the development of neurologic dysfunction if they continue on a gluten-containing diet. It is also unclear whether TG6 antibodies are present at the time of the initial immunologic response that leads to the development of enteropathy, or autoimmunity against TG6 is a late phenomenon. The significant difference in prevalence of TG6 antibodies between the 2 cohorts may account for geographical variations in the prevalence of neurologic manifestations.
Possible limitations of the study include the fact that the patients were selected from select clinics that specialize in patients with GRDs. This study demonstrates that antibodies against TG6 appear to be a sensitive and specific marker for GA, and suggests that it may be appropriate to redefine GA as idiopathic sporadic ataxia with circulating antibodies to TG6.
